Last reviewed · How we verify
A006
A006 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
A006 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | A006 |
|---|---|
| Sponsor | Amphastar Pharmaceuticals, Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, A006 reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism is particularly effective in patients with type 2 diabetes, as it helps to lower blood sugar levels and improve glycemic control.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006 (PHASE2)
- Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation (PHASE2)
- Dose-Ranging Study of A006 DPI, in Adult Asthma Patients (PHASE2)
- Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation (PHASE2)
- Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A006 CI brief — competitive landscape report
- A006 updates RSS · CI watch RSS
- Amphastar Pharmaceuticals, Inc. portfolio CI